RECRUITING

Predictors of Post-COVID Clinical and Cognitive Consequences

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The CDC describes Post-acute sequelae of SARS-COV-2 infection (PASC) for the wide range of physical and mental health consequences experienced by some patients. These sequelae may be present four or more weeks after SARS-COV-2 infection, including patients who had initial mild or asymptomatic acute infection. However, there is complete absence of data whether chronic sleep changes due to COVID-19 infection may influence these physical and mental health consequences. While fatigue is one of the common post-COVID conditions, there are no systematic examinations of sleep disturbances in COVID-19 survivors. This will be a pilot observational retrospective and prospective cohort study, to systematically assess if sleep disturbances and severity of sleep apnea comprise a modifiable facet of PASC as well as the short-term and longer-term effects of COVID-19 infection itself on sleep, cognitive function, exercise capacity and lung function.

Official Title

Predictors of Post-COVID Clinical and Cognitive Consequences

Quick Facts

Study Start:2023-01-19
Study Completion:2025-12-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06291870

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Not specified
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * All individuals 18 years or older, with prior history of COVID-19 infection diagnosis
  2. * Both genders including all racial and ethnic groups
  3. * Patients with OSA (apnea hypopnea index ≥ of 5/hour on polysomnography) with history of COVID-19 infection will be eligible with prior history of COVID-19 infection and without COVID-19 for Aim 2
  1. * Inability to give consent
  2. * Active suicidal symptoms
  3. * Children of all ages
  4. * Pregnant women

Contacts and Locations

Study Contact

Ruchi Rastogi, MS
CONTACT
(313) 576-4464
ruchi.rastogi@va.gov

Principal Investigator

Susmita Chowdhuri, MD, MS
PRINCIPAL_INVESTIGATOR
John D. Dingell VA Medical Center, Detroit, MI

Study Locations (Sites)

John D. Dingell VA Medical Center, Detroit, MI
Detroit, Michigan, 48201-1916
United States

Collaborators and Investigators

Sponsor: VA Office of Research and Development

  • Susmita Chowdhuri, MD, MS, PRINCIPAL_INVESTIGATOR, John D. Dingell VA Medical Center, Detroit, MI

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-01-19
Study Completion Date2025-12-30

Study Record Updates

Study Start Date2023-01-19
Study Completion Date2025-12-30

Terms related to this study

Keywords Provided by Researchers

  • COVID-19
  • Quality of Life
  • Neurocognitive Function
  • Sleepiness
  • Sleep Quality
  • Six minute walk
  • Fatigue

Additional Relevant MeSH Terms

  • Post Acute Sequelae of SARS CoV 2 Infection
  • Obstructive Sleep Apnea